Immunoproliferative Disorders
Welcome,         Profile    Billing    Logout  
 332 Companies   479 Products   479 Products   185 Mechanisms of Action   43 Trials   6723 News 


«12345678910111213...137138»
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment change, Trial withdrawal:  Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) -  Nov 26, 2018   
    P2,  N=0, Withdrawn, 
    N=30 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
    Enrollment change, Trial withdrawal:  HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) -  Nov 20, 2018   
    P1,  N=0, Withdrawn, 
    N=20 --> 11 | Trial completion date: Dec 2019 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; The clinical trial was terminated due to poor enrollment N=13 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  carfilzomib / Generic mfg., Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma (clinicaltrials.gov) -  Nov 19, 2018   
    P1/2,  N=8, Terminated, 
    N=13 --> 0 | Recruiting --> Withdrawn Trial completion date: Apr 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2019 --> May 2018; slow accrual
  • ||||||||||  Phase classification, Trial termination:  Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma (clinicaltrials.gov) -  Nov 16, 2018   
    P1,  N=3, Terminated, 
    Trial completion date: Apr 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2019 --> May 2018; slow accrual Phase classification: P=N/A --> P1 | Completed --> Terminated; Low accrual
  • ||||||||||  Phase classification, Trial completion date, Trial termination, Metastases:  Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (clinicaltrials.gov) -  Nov 7, 2018   
    P=N/A,  N=11, Terminated, 
    Completed --> Terminated Phase classification: P2 --> P=N/A | Trial completion date: Aug 2017 --> Apr 2017 | Active, not recruiting --> Terminated; PI left the department; protocol transfer did not take place.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies (clinicaltrials.gov) -  Oct 18, 2018   
    P2,  N=31, Completed, 
    Trial completion date: Jan 2019 --> May 2019 Recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2018 | Trial primary completion date: Dec 2016 --> Jun 2018
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Post-transplantation:  Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) -  Oct 17, 2018   
    P1,  N=127, Completed, 
    Recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2018 | Trial primary completion date: Dec 2016 --> Jun 2018 Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma (clinicaltrials.gov) -  Oct 17, 2018   
    P1,  N=6, Terminated, 
    Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018 N=25 --> 6 | Trial completion date: Jun 2019 --> Jul 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jul 2017; Low accrual
  • ||||||||||  decitabine / Generic mfg.
    Trial completion:  Phase I, Dose Escalation Study of Decitabine (clinicaltrials.gov) -  Oct 15, 2018   
    P1,  N=3, Completed, 
    Terminated --> Completed Active, not recruiting --> Completed
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial termination, Trial primary completion date:  BIBLOS: Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (clinicaltrials.gov) -  Oct 11, 2018   
    P1,  N=85, Terminated, 
    Phase classification: P2 --> P1 Trial completion date: Nov 2019 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Dec 2017; ANSM decision due to veino occlusive disease (security alert)
  • ||||||||||  buparlisib (AN2025) / Novartis, Adlai Nortye
    Phase classification:  Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Oct 10, 2018   
    P1,  N=7, Completed, 
    Trial completion date: Nov 2019 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Dec 2017; ANSM decision due to veino occlusive disease (security alert) Phase classification: P=N/A --> P1
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial completion date, Trial primary completion date, Pre-transplantation, Post-transplantation:  Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) -  Sep 21, 2018   
    P1/2,  N=67, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2018 | Trial primary completion date: Jan 2020 --> Jul 2018 Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Nov 2018
  • ||||||||||  alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
    Enrollment closed, Enrollment change, Trial primary completion date:  Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) -  Sep 19, 2018   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Nov 2018 Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
  • ||||||||||  Trial completion, Phase classification:  124I-FIAU Imaging in EBV and KSHV Associated Cancers (clinicaltrials.gov) -  Sep 17, 2018   
    P=N/A,  N=12, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Cardiac Fibrosis by CMR in Patients With Cancer (clinicaltrials.gov) -  Sep 14, 2018   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Completed | Phase classification: P1 --> PN/A N=12 --> 0 | Trial completion date: Feb 2019 --> Aug 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Aug 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Genetic Study of Families With High Frequency of Hodgkin Lymphoma (clinicaltrials.gov) -  Sep 12, 2018   
    P=N/A,  N=27, Completed, 
    Phase classification: P1/2 --> P1 | Trial primary completion date: Jul 2018 --> Apr 2017 Recruiting --> Completed | N=50 --> 27 | Trial completion date: Jul 2019 --> Feb 2018 | Trial primary completion date: Jul 2019 --> Feb 2018
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) -  Sep 10, 2018   
    P1,  N=20, Completed, 
    Trial primary completion date: Jan 2100 --> Oct 2018 N=15 --> 20 | Trial completion date: Jun 2018 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Apr 2016 | Active, not recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg., carboplatin / Generic mfg., bendamustine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma (clinicaltrials.gov) -  Sep 6, 2018   
    P2,  N=30, Completed, 
    Trial primary completion date: Jun 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2017 | Trial primary completion date: Jul 2018 --> Sep 2017
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial completion, Trial completion date:  BRAN: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas (clinicaltrials.gov) -  Sep 6, 2018   
    P2,  N=33, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2017 | Trial primary completion date: Jul 2018 --> Sep 2017 Recruiting --> Completed | Trial completion date: Dec 2018 --> Sep 2018
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion date, Trial termination, Trial primary completion date:  ROBIN: A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. (clinicaltrials.gov) -  Sep 4, 2018   
    P3,  N=88, Terminated, 
    Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2018 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Ongoing challenges to successfully recruit the required number of subjects
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change, Trial termination:  Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Sep 4, 2018   
    P2,  N=16, Terminated, 
    Trial completion date: Dec 2018 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Ongoing challenges to successfully recruit the required number of subjects N=40 --> 16 | Completed --> Terminated; slow accrual/lack of resources/low priority due to combining 2 consortia
  • ||||||||||  cyclophosphamide / Generic mfg., busulfan / Generic mfg.
    Trial completion, Enrollment change, Post-transplantation:  Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) -  Aug 31, 2018   
    P2,  N=142, Completed, 
    N=40 --> 16 | Completed --> Terminated; slow accrual/lack of resources/low priority due to combining 2 consortia Active, not recruiting --> Completed | N=92 --> 142